Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 6616 AL 6630

SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study

Maher-Edwards G, Dixon R, Hunter J, Gold M, Hopton G, Jacobs G, Hunter J, Williams P.

Int J Geriatr Psychiatry. 2011 May;26(5):536-44. doi: 10.1002/gps.2562. Epub 2010 Sep 24.

JNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer's and various neurodegenerative abnormalities

Mehan S, Meena H, Sharma D, Sankhla R.

J Mol Neurosci. 2011 Mar;43(3):376-90. doi: 10.1007/s12031-010-9454-6. Epub 2010 Sep 28.

Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease

Parnetti L, Chiasserini D, Andreasson U, Ohlson M, Hüls C, Zetterberg H, Minthon L, Wallin AK, Andreasen N, Talesa VN, Blennow K.

Acta Neurol Scand. 2011 Aug;124(2):122-9. doi: 10.1111/j.1600-0404.2010.01435.x. Epub 2010 Sep 29.

Transport of drugs across the blood-brain barrier in Alzheimer's disease

Nicolazzo JA, Mehta DC.

Ther Deliv. 2010 Oct;1(4):595-611. doi: 10.4155/tde.10.41.

Savings from sub-groups?: Policy guidance and Alzheimer's disease treatments

McNamee P, Vanoli A, Hutchings D, McKeith I, Bond J.

J Nutr Health Aging. 2010 Oct;14(8):664-8. doi: 10.1007/s12603-010-0313-5.

Developmental exposure to lead and late life abnormalities of nervous system

Basha R, Reddy GR.

Indian J Exp Biol. 2010 Jul;48(7):636-41.

Phenserine efficacy in Alzheimer's disease

Winblad B, Giacobini E, Frölich L, Friedhoff LT, Bruinsma G, Becker RE, Greig NH.

J Alzheimers Dis. 2010;22(4):1201-8. doi: 10.3233/JAD-2010-101311.

The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease

Cappell J, Herrmann N, Cornish S, Lanctôt KL.

CNS Drugs. 2010 Nov;24(11):909-27. doi: 10.2165/11539530-000000000-00000.

Investigational medications for treatment of patients with Alzheimer disease

Potter PE.

J Am Osteopath Assoc. 2010 Sep;110(9 Suppl 8):S27-36.

Recruitment of subjects into clinical trials for Alzheimer disease

Knebl JA, Patki D.

J Am Osteopath Assoc. 2010 Sep;110(9 Suppl 8):S43-9.

Phosphodiesterase-5 inhibitors: novel weapons against Alzheimer's disease?

Sabayan B, Zamiri N, Farshchizarabi S, Sabayan B.

Int J Neurosci. 2010 Dec;120(12):746-51. doi: 10.3109/00207454.2010.520381. Epub 2010 Oct 13.

Novel drug targets based on metallobiology of Alzheimer's disease

Bandyopadhyay S, Huang X, Lahiri DK, Rogers JT.

Expert Opin Ther Targets. 2010 Nov;14(11):1177-97. doi: 10.1517/14728222.2010.525352.

Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease

da Cruz e Silva OA, Henriques AG, Domingues SC, da Cruz e Silva EF.

CNS Neurol Disord Drug Targets. 2010 Dec;9(6):720-6. doi: 10.2174/187152710793237458.

[Glucagon-like peptide 1: a novel therapeutic strategy for Alzheimer's disease]

Wang XH, Yang W, Qi JS.

Sheng Li Xue Bao. 2010 Oct 25;62(5):398-406.

[Molecular targeted therapy in Alzheimer disease]

Morohashi Y, Tomita T, Iwatsubo T.

Nihon Rinsho. 2010 Oct;68(10):1906-10.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias